177 related articles for article (PubMed ID: 32214793)
1. Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE.
Elbarky AM
Clin Ophthalmol; 2020; 14():823-830. PubMed ID: 32214793
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results.
Elbarky AM
Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in the UAE: 24 and 36-month outcomes.
Elbarky A
Eur J Ophthalmol; 2022 Sep; ():11206721221128671. PubMed ID: 36168254
[TBL] [Abstract][Full Text] [Related]
4. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
6. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study.
Mathis T; Papegaey M; Ricard C; Rezkallah A; Matonti F; Sudhalkar A; Vartin C; Dot C; Kodjikian L
Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456557
[TBL] [Abstract][Full Text] [Related]
8. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME).
McCluskey JD; Kaufman PL; Wynne K; Lewis G
Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396
[No Abstract] [Full Text] [Related]
9. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
[TBL] [Abstract][Full Text] [Related]
10. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
[TBL] [Abstract][Full Text] [Related]
11. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
12. Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema - A Single Center Study.
Soares RM; Ferreira CC; Fernandes JDS; Madeira C; Silva LMA; Saraiva E; Ribeiro L; Fonseca S
Clin Ophthalmol; 2024; 18():1057-1066. PubMed ID: 38646183
[TBL] [Abstract][Full Text] [Related]
13. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
14. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.
Schmit-Eilenberger VK
Clin Ophthalmol; 2015; 9():801-11. PubMed ID: 25999689
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy.
Lima-Fontes M; Leuzinger-Dias M; Barros-Pereira R; Fernandes V; Falcão M; Falcão-Reis F; Rocha-Sousa A; Alves-Faria P
Ophthalmol Ther; 2023 Feb; 12(1):377-388. PubMed ID: 36417092
[TBL] [Abstract][Full Text] [Related]
16. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F;
Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience with fluocinolone acetonide intravitreal implant in patients with diabetic macular edema.
Capone L; Airaghi P; Aragona P; Castellino N; Cicinelli MV; Ciucci F; Coppola M; Gaetano C; Lattanzio R; Lorusso M; Maceroni M; Malvasi ME; Marco L; Marraffa M; Martini G; Mastropasqua R; Minnella AM; Nikolopulou E; Ortisi E; Pacella E; Papa V; Pennesi C; Reibaldi M; Rizzo S; Toto L; Trombetta L; Bandello F
Eur J Ophthalmol; 2024 Feb; ():11206721241235266. PubMed ID: 38396370
[TBL] [Abstract][Full Text] [Related]
18. BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA.
Gonzalez VH; Luo C; Almeida DRP; Cutino A; Coughlin B; Kasper J; Kiernan DF; ; ;
Retina; 2023 Aug; 43(8):1301-1307. PubMed ID: 37130434
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
Currie CJ; Holden SE; Berni E; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
[TBL] [Abstract][Full Text] [Related]
20. The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema.
Eaton A; Koh SS; Jimenez J; Riemann CD
Ophthalmol Ther; 2019 Mar; 8(1):51-62. PubMed ID: 30560505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
